Long noncoding RNAs (lncRNAs) consist of 200 nucleotide sequences that play essential roles in different processes, including cell proliferation, and differentiation. There is evidence showing that the dysregulation of lncRNAs promoter of CDKN1A antisense DNA damage-activated RNA (PANDAR) leads to the development and progression in several cancers including colorectal cancer, via p53-dependent manner. This suggests that these lncRNAs may be of value as prognostic indices and a therapeutic target, as a high expression of lncRNAs PANDAR is associated with poor prognosis. Furthermore, modulating lncRNAs PANDAR has been reported to induce apoptosis and inhibit the tumor growth through modulation of cell cycle and epithelial-mesenchymal transition (EMT) pathway. The aim of the current review was to provide an overview of the prognostic and therapeutic values of lncRNAs PANDAR in colorectal cancer.
Bibliographical noteACKNOWLEDGMENT: This work was supported by a grant from National Institute for Medical research Development, Grant No. 962782 (A. Avan).
- colorectal cancer
- lncRNAs promoter of CDKN1A antisense DNA damage-activated RNA (PANDAR)
- long noncoding RNAs (lncRNAs)
- prognostic biomarker
- therapeutic target